Rare disease focus Novelion Therapeutics specializes in rare disease therapies and has a portfolio including MYALEPT and JUXTAPID, presenting opportunities to partner or expand distribution within niche, high-need patient populations and payer programs.

Aegerion legacy Aegerion Pharmaceuticals under Novelion provides an existing product line with approved indications such as HoFH, and potential for regional license deals or co-promotion in new markets leveraging established regulatory and clinical data.

Global licensing Past and ongoing licensing activity with Recordati and international distributors for Juxtapid suggests a receptivity to partner on commercialization in Japan and other regions, indicating a pathway for new collaborations and market access deals.

Financial leverage With revenue under 1 million and a history of corporate activity (acquisitions and leadership changes), there is room to present bundled value plays, such as strategic financings, partnership-based development funds, or milestone-based licensing arrangements.

Strategic expansion signals Mergers and acquisitions history and shifts in leadership point to a company open to strategic deals, joint ventures, or asset-centric transactions that could accelerate clinical development programs or portfolio expansion in rare disease therapies.